GZMB and neoplasm: With the capability of identifying specific T cells necessary for effective tumor immunotherapy through measuring the activity of granzyme B, a microfluidic platform has shown the potential in evaluating the sensitivity of immunotherapy (Figure 4B) (Briones et al., 2020).